Drug Trial Radar · NCT02167893
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"
Last checked: Nov 19, 2026Latest source record: Mar 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11,288
Actual
Start
Oct 2005
Primary completion
Dec 2010
Study completion Dec 2010
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 19, 2014
Design
- Study type
- Observational
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this survey is designed to evaluate the efficacy and safety of long-term use (96 weeks) of leuprorelin acetate SR 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit) in prostate cancer participants in daily medical practice.
Conditions
- Prostate Cancer
Interventions
Leuprorelin acetateDrug
Leuprorelin acetate SR 11.25 mg injection kit
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting One or More Adverse Drug ReactionsTime frame: Baseline up to Week 96
- Number of Participants Reporting One or More Serious Adverse Drug ReactionsTime frame: Baseline up to Week 96
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.